Extended Data Fig. 2: Antibody responses to adjuvanted RBD–NP immunization.
From: Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
a, Serum neutralizing antibodies (nAb) titres determined using a SARS-CoV-2 S pseudovirus entry assay at day -7, 21 and 42. b, Pseudovirus nAb response against human convalescent sera from 4 COVID-19 patients. c, Spearman’s correlation between pseudovirus and authentic virus nAb titres measured at day 42. d, RBD–NP-specific IgG secreting plasmablast response measured at day 4 post-secondary vaccination using ELISPOT. Boxes show median, 25th and 75th percentiles and the whiskers show the range. e, Spearman’s correlation between plasmablast response on day 25 and pseudovirus nAb titre measured at day 42. f, Pseudovirus nAb response measured in the AS03 durability group at time points indicated on the x axis. g, ACE2 blocking measured in sera collected at time points indicated on the x axis. h, SARS-CoV-2 nAb titres against pseudovirus wild-type containing D614G mutation on the Wuhan-1 spike (circles) or the B.1.1.7 variant (squares) strain measured in day 42 sera. The difference between groups in a and d was analysed using two-sided Mann–Whitney rank-sum test. The error bands in c and e represent 95% confidence limits. N = 4 for O/W, 10 for AS03 and 5 for all other groups.
